A Trial Assessing The Long Term Safety And Tolerability Of [S,S]-Reboxetine In Patients With Post-Shingles Pain.
Phase 2
Terminated
- Conditions
- Pain
- Interventions
- Drug: [S,S]-Reboxetine
- Registration Number
- NCT00353808
- Lead Sponsor
- Pfizer
- Brief Summary
The purpose of this study is to assess the long-term safety and tolerability of \[S,S\]-Reboxetine in patients with chronic pain following shingles. This is the extension study of Protocol A6061026.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 112
Inclusion Criteria
- Patients must have met the patient selection criteria for the preceding double-blind Protocol A6061026 and have completed the 16-week trial.
- Patients at screening must have a score of >/=40mm on the pain visual analogue scale.
Read More
Exclusion Criteria
- Serious adverse event during the preceding double-blind Protocol A6061026 that was determined to be related to the trial medication by the Investigator.
- Patient treatment compliance was less than 80% in the preceding double-blind Protocol A6061026.
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description s, s reboxetine [S,S]-Reboxetine -
- Primary Outcome Measures
Name Time Method Vital signs Physical examination 12-lead ECG Hematology/Biochemistry Adverse events
- Secondary Outcome Measures
Name Time Method Pain Visual Analogue Scale Patient Global Impression of Change
Trial Locations
- Locations (1)
Pfizer Investigational Site
🇺🇸Tacoma, Washington, United States